CSIMarket
 


Avrobio Inc   (AVRO)
Other Ticker:  
 
 

AVRO's Net Cash Flow Growth by Quarter and Year

Avrobio Inc 's Net Cash Flow results by quarter and year




AVRO Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -97.21 -11.80 40.14
III Quarter September -18.85 57.16 -25.07 -24.83
II Quarter June 52.76 -29.25 -6.59 -13.32
I Quarter March -20.24 -27.90 -26.66 70.65
FY   13.67 -97.20 -70.12 72.64



AVRO Net Cash Flow third quarter 2023 Y/Y Growth Comment
Avrobio Inc in the third quarter 2023 recorded net cash outflow of $ -18.85 millions.

According to the results reported in the third quarter 2023, Avrobio Inc achieved the best Net Cash Flow growth in Biotechnology & Pharmaceuticals industry. While Avrobio Inc ' s Net Cash Flow no change of % ranks overall at the positon no. in the third quarter 2023.




AVRO Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -33.92 %
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - 19.59 %

Financial Statements
Avrobio Inc 's third quarter 2023 Net Cash Flow $ -18.85 millions AVRO's Income Statement
Avrobio Inc 's third quarter 2022 Net Cash Flow $ 57.16 millions Quarterly AVRO's Income Statement
New: More AVRO's historic Net Cash Flow Growth >>


AVRO Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - 16.32 %
FY (Year on Year)   - - - 19.59 %




Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Avrobio Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AVRO's III. Quarter Q/Q Net Cash Flow Comment
Current net cash outflow of -18.85 millions by Avrobio Inc come out even more unfavourable considering the net cash outflow 52.76 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Avrobio Inc achieved highest sequential Net Cash Flow growth. While Avrobio Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AVRO's III. Quarter Q/Q Net Cash Flow Comment
III. Quarter 2023 results of -18.85 millions by Avrobio Inc look even more unfavourable compare to the 52.76 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Avrobio Inc achieved highest sequential Net Cash Flow growth. While Avrobio Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Avrobio Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Net Cash Flow 12 Months Ending $ -83.53 $ -7.53 $ -89.55 $ -97.21 $ -11.80
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) - - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # # # # #




Cumulative Net Cash Flow growth Comment
Avrobio Inc ' has realized cumulative trailing twelve months net cash outflow of $ -84 millions in the Sep 30 2023 period.
The situation is detiriorating as the cumulative net cash outflow is becoming larger from $ -7.53 millions in the twelve months ending a quarter before and $ -94.029 millions from the TTM period ending Sep 30 2022.

Avrobio Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Cash Flow growth Comment
Avrobio Inc ' has realized cumulative trailing twelve months net cash outflow of $ -84 millions in the Sep 30 2023 period.
The business is detiriorating as the cumulative net cash outflow is becoming larger from $ -7.53 millions in TTM ending quarter Jun 30 2023 and $ -94.029 millions for the twelve months ending in the quarter Sep 30 2022 Maria Clark mentioned.

Avrobio Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Cash Flow Growth
Biotechnology & Pharmaceuticals Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
AVRO's Net Cash Flow Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for AVRO's Competitors
Net Cash Flow Growth for Avrobio Inc 's Suppliers
Net Cash Flow Growth for AVRO's Customers

You may also want to know
AVRO's Annual Growth Rates AVRO's Profitability Ratios AVRO's Asset Turnover Ratio AVRO's Dividend Growth
AVRO's Roe AVRO's Valuation Ratios AVRO's Financial Strength Ratios AVRO's Dividend Payout Ratio
AVRO's Roa AVRO's Inventory Turnover Ratio AVRO's Growth Rates AVRO's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Sep 30 2023
Nascent Biotech Inc-4.04%$ -4.038 millions
Halozyme Therapeutics Inc -5.63%$ -5.629 millions
Vystar Corporation-6.05%$ -6.052 millions
Ideaya Biosciences Inc -7.27%$ -7.268 millions
Phibro Animal Health Corporation-7.87%$ -7.874 millions
Luna Innovations Inc-9.06%$ -9.058 millions
Puma Biotechnology Inc -13.53%$ -13.534 millions
Fulgent Genetics Inc -14.21%$ -14.211 millions
Prestige Consumer Healthcare Inc -16.52%$ -16.522 millions
Omniab Inc -20.57%$ -20.566 millions
Gossamer Bio Inc -22.91%$ -22.914 millions
Alnylam Pharmaceuticals Inc -24.60%$ -24.599 millions
Emmaus Life Sciences Inc -26.90%$ -26.904 millions
Kala Bio inc -27.38%$ -27.384 millions
Protara Therapeutics Inc -29.54%$ -29.540 millions
Msa Safety Incorporated-31.72%$ -31.716 millions
Avalo Therapeutics Inc -32.14%$ -32.143 millions
Biovie Inc -32.27%$ -32.265 millions
Veracyte inc -32.97%$ -32.966 millions
Coherus Biosciences inc -35.07%$ -35.068 millions
Biomarin Pharmaceutical Inc-35.76%$ -35.762 millions
International Stem Cell Corporation-40.00%$ -40.000 millions
Arvinas Inc -42.82%$ -42.822 millions
89bio Inc -44.85%$ -44.846 millions
Assertio Holdings inc -46.56%$ -46.561 millions
Infusystem Holdings Inc-48.08%$ -48.077 millions
Eqrx Inc -48.96%$ -48.965 millions
Privia Health Group Inc -49.62%$ -49.617 millions
Nektar Therapeutics-49.69%$ -49.693 millions
Avinger Inc -53.79%$ -53.788 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com